+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii

Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii

Clinical Infectious Diseases 20 Suppl 2: S266-S268

(PDF emailed within 0-6 h: $19.90)

Accession: 033119102

Download citation: RISBibTeXText

PMID: 7548571

DOI: 10.1093/clinids/20.supplement_2.s266

Related references

Administering Intravenous Immune Globulin for a Patient With Clostridium difficile Infection and Acute Renal Failure. Infectious Disease in Clinical Practice 18(3): 211-215, 2010

Saccharomyces boulardii in a child with recurrent Clostridium difficile. Pediatrics International 51(1): 156-158, 2009

Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Alimentary Pharmacology & Therapeutics 13(12): 1663-1668, 1999

Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. American Journal of Gastroenterology 84(10): 1285-1287, 1989

Pharmacodynamic behavior of Saccharomyces boulardii in patients with recurrent Clostridium difficile disease. Microbial Ecology in Health & Disease 12(2): 117-118, 2000

Saccharomyces boulardii stimulates an intestinal IGA immune response to Clostridium difficile toxin a in mice. Gastroenterology 116(4 PART 2): A894, April, 1999

Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection. Journal of Gastrointestinal and Liver Diseases 24(1): 21-24, 2016

Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Canadian Journal of Gastroenterology 23(12): 817-821, 2010

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clinical Infectious Diseases 31(4): 1012-1017, 2000

Saccharomyces boulardii prevents recurrent Clostridium difficile pseudomembranous colitis and diarrhea A multicenter controlled trial. Gastroenterology 104(4 SUPPL ): A786, 1993

Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infection and Immunity 69(4): 2762-2765, 2001

Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection. American Journal of Health-System Pharmacy 72(12): 1013-1019, 2016

Risks of Saccharomyces boulardii-Containing Probiotics for the Prevention of Clostridium difficile Infection in the Elderly. Gastroenterology 153(5): 1450-1451, 2017

Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study. European Journal of Clinical Microbiology & Infectious Diseases, 2018

Immune Thrombocytopenia Caused by Fecal Microbial Transplantation in a Patient With Severe Recurrent Clostridium difficile Infection. Journal of Clinical Gastroenterology 49(10): 888-889, 2016